Tamibarotene (Rege Nephro)

他米巴罗汀（Rege Nephro）

Report date: 2024/11/26 11:55:49

Base Information

Drug NameTamibarotene (Rege Nephro)
Drug Alias NameRN-014
ClassificationSmall molecules
Mechanisms of ActionRetinoic acid receptor alpha agonistsRetinoic acid receptor beta agonists
TargetsRetinoic acid receptor alphaRetinoic acid receptor beta
Therapy Area/IndicationsPolycystic Kidney, Autosomal Dominant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRege Nephro Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRege Nephro Co Ltd
Inactive CompaniesN/A
Active IndicationsPolycystic Kidney, Autosomal Dominant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A